Last reviewed · How we verify

NCT06880965

Effect of Concentrated Growth Factors on Short Implant-Supported Overdentures

Completed Phase 2, PHASE3 Last updated 18 March 2025
What this trial tests

Phase 2, PHASE3 trial testing testing implant stability in Partially Edentulous Patients in 10 participants. Completed in 4 December 2024.

Timeline
24 August 2023
Primary endpoint
25 November 2024
4 December 2024

Quick facts

Lead sponsorTanta University
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposehealth services research
Enrollment10
Start date24 August 2023
Primary completion25 November 2024
Estimated completion4 December 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

Adults 20 to 65, any sex, with Partially Edentulous Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study will be to evaluate the effect of concentrated growth factors on stability and radiographic outcome of short implant supported mandibular assisted overdenture

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Partially Edentulous Patients

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06880965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing